Researchers have identified a promising new strategy to combat obesity-related leukemia by combining GLP-1 weight-loss drugs with anti-inflammatory medications. The study found that obesity promotes leukemia growth by triggering chronic inflammation and disrupting normal metabolic signaling. In mouse models, combining a GLP-1 drug with an IL-17A-blocking therapy reduced leukemia burden, improved immune function, and slowed disease progression. Because both types of drugs are already approved for other conditions, the findings could accelerate future clinical trials. While the results are encouraging, further research is needed to confirm whether this combination therapy is safe and effective in people with obesity-associated leukemia.
Read more at NewsMedical